Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “ziv-aflibercept” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 9
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 9 pipeline programs matching "ziv-aflibercept" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

9 results for “ziv-aflibercept” Back to intelligence hub

Search results

  1. EFC10261

    Regeneron UK Limited

    Carcinoma

    phase 3 small molecule completed

    1 trial
  2. EFC10547

    Regeneron UK Limited

    Pancreatic Neoplasm

    phase 3 small molecule terminated

    1 trial
  3. EFC6125

    Regeneron UK Limited

    Ovarian Neoplasms

    phase 3 small molecule completed

    2 trials
  4. ARD6122

    Regeneron UK Limited

    Neoplasms

    phase 2 small molecule completed

    1 trial
  5. ARD6123

    Regeneron UK Limited

    Pulmonary Diseases

    phase 2 small molecule completed

    1 trial
  6. ZIV-Aflibercept

    Regeneron UK Limited

    Metastatic Uveal Melanoma

    phase 2 small molecule active

    1 trial
  7. Ziv-Aflibercept

    Regeneron UK Limited

    Uveal Melanoma

    phase 2 mab terminated

    1 trial
  8. ziv-aflibercept

    Regeneron UK Limited

    Lymphoma

    phase 1 mab completed

    2 trials
  9. ziv-aflibercept

    Regeneron UK Limited

    Cancer

    phase 1 mab completed

    2 trials

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.